CEO Innovation Lecture Series
This series of lectures exposes participants to the latest ideas of the finest CEO innovators. Join us to learn how innovation can benefit and grow your organization.
9th Annual CEO Innovation Lecture
Robert Hugin, Chairman and CEO, Celgene Corporation
Mr. Hugin serves as Chairman and Chief Executive Officer of Celgene Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and immune-inflammatory disease. He joined Celgene in June 1999 and has been a Director of the company since December 2001. Mr. Hugin is immediate past Chairman of the Board of The Pharmaceutical Research and Manufacturers of America and is a member of the Board of Trustees of Princeton University, The Medicines Company, and The Darden Foundation, University of Virginia. He also serves as a member of the Board of Trustees of Atlantic Health System and of Family Promise, a national non-profit network assisting homeless families. Prior to joining Celgene, Mr. Hugin was a Managing Director with J.P. Morgan & Co. Inc. Mr. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985 and served as a United States Marine Corps infantry officer during the intervening period. Bob and his wife Kathy have three children and live in Summit, New Jersey.
The Rothman Institute has been making a difference in the lives of entrepreneurs, family business and students since 1989, and appreciates the contribution of those who have helped it advance its mission to teach and support entrepreneurship and innovation in the academic, business, and nonprofit communities. The innovation programs coordinated by the Institute reach into corporations and Fortune 500 companies in New Jersey and our focus on women’s entrepreneurship helps to support research into and growth of women-owned companies. The gala celebration of our achievements will help secure our continued contribution to the entrepreneurial and innovation ecosystem that make New Jersey such an exciting state to do business.
8th Annual CEO Innovation Lecture
Kurt Landgraf, President and CEO, ETS
Wednesday, November 20, 2013
Innovation and Entrepreneurship in Education: Challenges for Today, Results for Tomorrow
Kurt M. Landgraf joined ETS as President and Chief Executive Officer in 2000. Since then, he has overseen ETS’s entrance into the K–12 market, expanded its global business, broadened its education research activities, and nurtured its social mission through collaborations with groups serving underrepresented students.
Landgraf began his career at ETS more than 30 years ago, when he served as Associate Director of Marketing. Before returning to ETS in 2000, he held leadership positions at DuPont, including Chief Operating Officer, Chief Financial Officer and Chairman and Chief Executive Officer of the DuPont Pharmaceutical Company, and at the Upjohn Company.
Besides expanding ETS’s business and research activities, Landgraf has led the company’s efforts to help close the academic achievement gap between affluent and disadvantaged students. ETS has strengthened its ties to Historically Black Colleges and Universities, the National Urban League, the Hispanic Association of Colleges and Universities, the ASPIRA Association and Native American education groups. Landgraf also has led the establishment of innovative company programs to assist New Jersey communities and service groups and improve education.
Landgraf earned his bachelor’s degree in economics and business administration from Wagner College. He also holds three master’s degrees: an M.Ed. from Rutgers University, an M.A. in economics from Pennsylvania State University, and an M.S. in sociology from Western Michigan University. He is a graduate of the Harvard Business School Advanced Management Program, has received four honorary doctorates, and has taught college-level economics, sociology and labor relations at institutions throughout the United States.
7:15 a.m. Breakfast/Registration
8:00 a.m. Welcome
8:10 a.m. Lecture: Kurt Landgraf, ETS
8:45 a.m. Q & A
9:00 a.m. Networking
Lenfell Hall, Hennessy Hall (Mansion)
Fairleigh Dickinson University's College at Florham
285 Madison Avenue, Madison, NJ 07940
Register Here! Eventbrite
Questions? Please call 973-443-8842.
Previous CEO Lectures
7th Annual CEO Innovation Lecture
Brent Saunders, President and CEO, Bausch + Lomb
Monday, December 10, 2012
The Innovation Landscape - A Vision From Eye Health
Brent Saunders is the president and chief executive officer of Bausch + Lomb, a leading global eye health company. He was appointed to this
position in March 2010. Mr. Saunders has significant healthcare industry expertise and a proven track-record leading business transformations and integrations. Most recently he held the position of president of Global Consumer Health Care at Schering-Plough and was named head of integration for the company’s merger with Merck & Co. and for Schering Plough’s acquisition of Organon BioSciences.
Before joining Schering-Plough, Mr. Saunders was a partner and head of Compliance Business Advisory at PricewaterhouseCoopers LLP. Prior to that, he was chief risk officer at Coventry Health Care and senior vice president, Compliance, Legal and Regulatory at Home Care Corporation of America. Mr. Saunders began his career as chief compliance officer for the Thomas Jefferson University Health System.
Mr. Saunders serves on the Board of Directors of Forest Laboratories and the Overlook Foundation. He is a member of the Federal Reserve Bank of New York's Upstate Regional Advisory Board, and he is also a member of the Board of Trustees of the University of Pittsburgh. Mr. Saunders earned his MBA from Temple University School of Business, his J.D. from Temple University School of Law and his bachelor’s degree from the University of Pittsburgh.
8:15 a.m. Breakfast/Registration
9:00 a.m. Welcome
9:10 a.m. Lecture: Brent Saunders, Bausch + Lomb
9:45 a.m. Q & A
10:00 a.m. Networking
Lenfell Hall, Hennessy Hall (Mansion)
Fairleigh Dickinson University's College at Florham
285 Madison Avenue, Madison, NJ 07940
Questions? Please call 973-443-8842.
6th Annual CEO Innovation Lecture
Francisco D'Souza, President and CEO, Cognizant
Friday, November 18, 2011
Leading Through Uncertainty
Francisco D’Souza is the President and CEO of Cognizant (NASDAQ: CTSH), a leading global provider of information technology, consulting, and business process outsourcing services. Francisco’s leadership inspires more than 111,000 business and technology professionals who manage projects delivered from 40 countries. Since Francisco’s promotion to CEO in 2007, company revenues have tripled to more than $4.5 billion fueling Cognizant’s rise to the Fortune 500, where it debuted at number 484 earlier this year. In its first-ever appearance on the Barron's 500 in May, Cognizant ranked 42nd among S&P 500 companies.
Francisco was named one of the nation’s best CEOs in Institutional Investor’s 2011 and 2010 All-America Executive Team ranking. He also received an Ernst & Young Entrepreneur of the Year award and serves on the Board of Trustees of Carnegie Mellon University and The New York Hall of Science. Francisco earned his bachelor's degree from the University of East Asia and his M.B.A. from Carnegie Mellon University.
5th Annual CEO Innovation Lecture
Daniel Vasella, Chairman of Novartis
Thursday November 11, 2010
Improving the Practice of Medicine: The Role of Drug Discovery and Health Care Systems
Daniel Vasella, M.D., is Chairman of the Board of Directors for Novartis AG.
He served as CEO and executive member of the Board of Directors for 14 years following the merger that created Novartis in 1996. During his tenure as CEO, he has led Novartis through dynamic growth to rank among the world’s most successful healthcare companies, and strategically refocused the portfolio to include pharmaceuticals, vaccines and diagnostics, generics and consumer health.
As Chairman and CEO, Dr. Vasella enhanced the company’s corporate governance policies in line with best practices and listed Novartis on the New York Stock Exchange. He has also strengthened the research capacity of Novartis in leading technologies by creating the Novartis Institute for BioMedical Research. He established The Genomics Institute of the Novartis Research Foundation, which is focused on developing therapeutics from the data generated from the mapping of the human genome.
Dr. Vasella has implemented strong pioneering initiatives to ensure access to medicines, which include the founding of the Novartis Institute for Tropical Diseases for research on neglected diseases of the developing world, the International Patient Assistance Program for the breakthrough cancer drug Gleevec/Glivec, the supply of the novel malaria treatment Coartem below cost to the World Health Organization and other institutions as well as a pledge to donate the drug therapy needed to eradicate leprosy worldwide. Furthermore, under Dr. Vasella’s leadership, Novartis was one of the first multinational companies to sign the UN Global Compact initiative.
TD Bank, America's Most Convenient Bank® is one of the 15 largest banks in the U.S., with more than 22,000 employees and deep roots in the community dating back more than 150 years. The Bank offers a broad array of retail, small business and commercial banking products and services to more than 6.5 million Customers through its extensive network of more than 1,100 retail locations throughout the Northeast, Mid-Atlantic, Florida and Metro D.C. TD Bank is a member of TD Bank Financial Group of Toronto, Canada, a top 10 financial services company in North America and one of a few banks in the world rated Aaa by Moody's. TD Bank Financial Group trades on the New York and Toronto stock exchanges under the ticker: TD. www.tdbank.com.
Chairman and CEO, Avon Products
Thursday, November 19, 2009
Innovation - The Key to Navigating the Shifting Economic Landscape
Andrea Jung, Chairman and Chief Executive Officer of Avon Products, is responsible for developing and executing all of the company’s long-term growth strategies, launching new brand initiatives, developing earnings opportunities for women worldwide, and defining Avon as the premier direct seller of beauty products. Ms. Jung was appointed CEO in 1999 and elected Chairman in 2001. She has been a member of the Board of Directors since January 1998.
Prior to her current role, Ms. Jung was President and Chief Operating Officer, with full P&L responsibility for Avon’s business units worldwide. From 1996 to 1998, she ascended to senior level positions within Avon’s product marketing group, where she oversaw research and development, market research, strategic planning, joint ventures and alliances.
Ms. Jung joined the company in January 1994 as President, Product Marketing Group, Avon U.S. Before joining Avon, Ms. Jung was Executive Vice President at Neiman Marcus from 1991 to 1993, responsible for accessories, cosmetics and women’s, intimate and children’s apparel. Prior to that, she was Senior Vice President, General Merchandising Manager, at I. Magnin from 1987 to 1991.
In 2008, Ms. Jung was appointed Chair of the World Federation of Direct Selling Associations, (WFDSA). She became the first woman elected chair of the Cosmetic, Toiletry, and Fragrance Association in March 2001, a role she held until early 2005. She currently serves on the Board of Directors of the General Electric Company and Apple and is a member of the New York Presbyterian Hospital Board of Trustees and the Catalyst Board of Directors.
In 2008, Ms. Jung was ranked #19 on the Forbes list of “The World’s 100 Most Powerful Women”, and #5 on Fortune magazine's "50 Most Powerful Women in Business” list, which she has been on since the list’s inception. In addition, she has been ranked on TheWall Street Journal’s "50 Women to Watch,” since 2004, and was one of only 18 executives included in U.S News & World Report’s “America’s Best Leaders 2007.” Ms. Jung is a magna cum laude graduate of Princeton University and is fluent in Chinese (Mandarin).
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough’s vision is to “Earn Trust, Every Day” with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its web site is www.schering-plough.com.
3rd annual CEO Innovation Lecture
Ralph Izzo, Chairman, President and CEO,
Public Service Enterprise Group
November 5, 2008
speaking on "Innovation: The Future of Energy"
Ralph Izzo is chairman, president and CEO of Public Service Enterprise Group. PSEG is best known as the parent company of PSE&G, one of the largest utility companies in the nation and one of New Jersey’s leading companies since its establishment more than a century ago.
Today, PSEG is forging a path of leadership on the environment while remaining true to its commitment to delivering safe, reliable, affordable energy. While many companies say they are “going green,” PSEG prefers to let its actions do the talking — creating an innovative solar financing program, a proposal for an offshore wind farm and major investments in energyefficiency.
Izzo received his PhD in applied physics from Columbia University and began his career as a research scientist at the Princeton Plasma Physics Laboratory.
He became a well-known leader within the public policy arena through years of work in the offices of U.S. Senator Bill Bradley and New Jersey Governor Tom H. Kean.
2nd annual CEO Innovation Lecture Campbell Soup President and CEO,
Douglas R. Conant
Thursday, October 25, 2007
Douglas R. Conant was appointed President and Chief Executive Officer of Campbell Soup Company in January of 2001. He also was elected a Director of the company at that time. Conant is Campbell’s 11th leader in the company’s nearly 140-year history.
Under Conant’s leadership over the past 6 years, Campbell has reversed a precipitous decline in market value and employee engagement.The company has made significant investments to improve product quality and packaging, strengthen the effectiveness of its marketing programs, and develop a robust innovation pipeline.Campbell also has improved its financial profile, enhanced its relationships with its customers, and consistently improved its employee engagement through investments in its organization.Today, Campbell is delivering total shareowner returns in the top tier of the global food industry and displaying ever-improving employee engagement levels.As a result, the company is well on its way to achieving its mission of building the world’s most extraordinary food company by nourishing people’s lives everywhere, every day.
Inaugural CEO Innovation Lecture
Fred Hassan, Chairman and CEO,
Thursday, February 23, 2006
speaking on Customer Focus: A Prescription for Driving Innovation
Fred Hassan is chairman of the board and chief executive officer of Schering-Plough Corporation. His current position is the latest in a 30- year career committed to fostering innovation and science-centered entrepreneurship in the pharmaceutical industry. Hassan has a strong track record of executing transformational change in complex global companies, which led to sustained sales and earnings-per-share growth.
His leadership approach includes a deep focus on fostering attitudes and behaviors among colleagues that are critical to driving long-term high performance —including the behaviors of collaboration, shared accountability and listening and learning.Prior to joining Schering-Plough in April 2003, Hassan was chairman and chief executive officer of Pharmacia Corporation.
Previously, Hassan was executive vice president and a director of Wyeth, formerly known as American Home Products. Hassan also spent 17 years with Sandoz Pharmaceuticals (now Novartis). Hassan received a BS degree in chemical engineering from the University of London and an MBA from Harvard Business School.